Mergers & Acquisitions Mergers & Acquisitions

Race between Grail, rivals will be harmed by Illumina deal, US FTC tells court

By Jenna Ebersole and Austin Peay
  • 24 Aug 2021 17:32
  • 21 Oct 2021 05:27
Grail and its rivals are in a race on early-detection cancer screening tests even though Grail has the only product on the market so far, and the Illumina-Grail deal threatens innovation in the life-saving technology, a US Federal Trade Commission lawyer said today.

“The gun has gone off and the race has started,”

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News